biology

Tenosynovial giant cell tumor

Tenosynovial giant cell tumor is a biology topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Tenosynovial giant cell tumor rather than just read about it. In short: Tenosynovial giant cell tumor (TGCT) is a non-malignant tumor defined histologically as inclusions of "osteoclast-like" multinucleated giant cells, hemosiderin, and macrophages. This histology can present one of 2 clinically distinct ways.

Key takeaways

Tenosynovial giant cell tumor belongs to biology; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Tenosynovial giant cell tumor to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Tenosynovial giant cell tumor from memory before moving on to harder problems.

Reference excerpt

Tenosynovial giant cell tumor (TGCT) is a non-malignant tumor defined histologically as inclusions of "osteoclast-like" multinucleated giant cells, hemosiderin, and macrophages. This histology can present one of 2 clinically distinct ways. Localized/nodular TGCT (L-TGCT), sometimes referred to as "giant cell tumor of the tendon sheath"; is a common tumor that presents as a slow-growing, encapsulated, localized and limited bump, most frequently in the fingers. Diffuse TGCT (D-TGCT) — also called pigmented villonodular synovitis (PVNS)— is a rare tumor that presents as a proliferative, destructive, intra-articular lesion, most commonly in the knee. D-TGCT tumors often develop from the lining of joints (also known as synovial tissue).. Common symptoms of D-TGCT include swelling, pain, stiffness and reduced mobility in the affected joint or limb.

Classification Classification for TGCT encompasses two subtypes that can be divided according to site – within a joint (intra-articular) or outside of the joint (extra-articular) – and growth pattern (localized or diffuse) of the tumor(s). Localized and diffuse subsets of TGCT differ in their prognosis, clinical presentation, and biological behavior, but share a similar manner of disease development.

Localized TGCT

Localized TGCT is sometimes referred to as localized pigmented villonodular synovitis (L-PVNS), giant cell tumor of the tendon sheath (GCT-TS), nodular tenosynovitis, localized nodular tenosynovitis, and L-TGCT. The localized form of TGCT is more common. Localized TGCT tumors are typically 0.5 cm-4 cm), develop over years, are benign and non-destructive to the surrounding tissue, and may reoccur in the affected area. The most common symptom is painless swelling. Localized TGCT most often occurs in fingers, but can also occur in other joints.

Diffuse TGCT

Diffuse TGCT is sometimes referred to as pigmented villonodular synovitis (PVNS), conventional PVNS, and D-TGCT. Diffuse TGCT occurs less frequently and is locally aggressive (in some cases, tumors may infiltrate surrounding soft tissue). It most commonly affects people under 40 years old, though the age of occurrence varies. Diffuse TGCT may occur inside a joint (intra-articular) or outside of a joint (extra-articular). Intra-articular tumors typically occur in the knee (approximately 75% of cases) and hip (approximately 15% of cases). Extra-articular tumors are usually found in the knee, thigh, and foot. Symptoms include swelling, pain, sensitivity, and/or limited range of motion. The rate of reoccurrence is estimated to be 18-46% for intra-articular tumors and 33-50% for extra-articular tumors.

Complications Diffuse TGCT is locally aggressive and can spread to surrounding tissues, causing bone erosion and tissue damage. If not treated early, it can spread to areas outside the joint, extra-articular, and potentially cause permanent loss of range as well as intense pain.

Mechanism TGCT tumors grow due to genetic overexpression of colony stimulating factor 1. This causes colony-stimulating factor-1 receptor (CSF1R) cells to accumulate in the joint tissue.

Diagnosis TGCT can be diagnosed by magnetic resonance imaging (MRI), by biopsy, or during surgery. The disorder is difficult to identify and is often not diagnosed for years due to nonspecific symptoms or a general paucity of symptoms. TGCT cases are often misdiagnosed as osteoarthritis, localized trauma, sports injuries, xanthomas, or other conditions. One study of 122 diffuse TGCT patients found that the average delay in diagnosis was 2.9 years. To identify or monitor using MRI, the minimum techniques required include T1 weighted images, T2 weighted images, and a fluid sensitive sequence.

Treatment Patients affected by TGCT should be managed within expert centers or reference networks, by a dedicated, experienced sarcoma multidisciplinary treatment team, including a pathologist, radiologist, orthopaedic surgeon, pain specialist, surgical, radiation and medical oncologists. Patients initially treated at cancer centers have lower recurrence rates than those initially treated by community centers. Surgery has been the most common form of treatment for both localized and diffuse TGCT. After surgery, patients may receive physical therapy in order to help rehabilitate affected joints. However, recurrence of TGCT after surgery is common, with a higher rate of recurrence for diffuse TGCT than for localized TGCT. In cases of recurrent or resistant disease, multiple surgeries, total joint arthroplasties, or amputation may be required. A multidisciplinary approach, supplementing surgery or other treatments, can also improve outcomes in cases of recurrent TGCT. In the late 2010s, treatment with CSF1R inhibitors emerged as an option that may help improve functionality for patients with recurrent TGCT or TGCT that is not easily managed by surgery.An oral CSF-1R inhibitor pexidartinib is approved in the US and only available through a Risk Evaluation and Mitigation Strategy (REMS) Program, and two other oral CSF-1R inhibitors, pimicotinib and vimseltinib are being developed in phase 3 trials. There is insufficient and contradictory evidence on radiation therapy, in the form of radiosynoviorthesis (yttrium injections) or external beam, before or after surgery and thus no recommendation for its use in TGCT can be made. For asymptomatic patients, active surveillance is the preferred method. Active surveillance includes monitoring with MRI in intervals (e.g., every 6 months) to ensure the delay in treatment does not pose a potential harm. This should be carefully weighed against the potential for over treatment. Vimseltinib (Romvimza) was approved for medical use in the United States in February 2025.

Epidemiology A study conducted in the Netherlands estimated that the worldwide incidence of TGCT is 43 cases per million person-years. The majority – 39 cases per million person-years – were estimated to be localized TGCT; the remaining 4 cases per million person-years were estimated to be diffuse TGCT. TGCT can occur in patients of any age, but people with localized TGCT are typically between 30 and 50 years old, while diffuse TGCT tends to affect people under the age of 40.

See also Fibroma of tendon sheath List of cutaneous conditions

References

External links

Illustrations

Worked examples

Example 1 — a first encounter with Tenosynovial giant cell tumor

Start with the simplest possible case. Write down what Tenosynovial giant cell tumor claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Tenosynovial giant cell tumor before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Tenosynovial giant cell tumor ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Tenosynovial giant cell tumor

In research: Tenosynovial giant cell tumor appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Tenosynovial giant cell tumor in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Tenosynovial giant cell tumor is common in secondary-school and first-year university syllabi. It links to neighbouring topics Ailments of unknown cause, Dermal and subcutaneous growths, Musculoskeletal disorders, so understanding it makes those chapters shorter.
In everyday life: Look for Tenosynovial giant cell tumor outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Tenosynovial giant cell tumor” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Tenosynovial giant cell tumor in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Tenosynovial giant cell tumor means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Tenosynovial giant cell tumor out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Tenosynovial giant cell tumor in simple terms?

Why does Tenosynovial giant cell tumor matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Tenosynovial giant cell tumor?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Tenosynovial giant cell tumor.